Most Women With Breast Cancer Can Skip Chemo, According to New Study

(CHICAGO) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk. The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs. “The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most women in this situation don’t need treatment beyond surgery and hormone therapy, and “the rest of them are receiving chemotherapy unnecessarily.” The study was funded by the National Cancer Institute, some foundations and proceeds from the U.S. breast cancer postage stamp. Results were discussed Sunday at an American Society of Clinical Oncology conference in Chicago and published by the New England Journal of Medicine. Some study leaders consult for breast cancer drugmakers or for the company that makes the gene test. MOVING AWAY FROM CHEMO Cancer care has been evolving away from chemotherapy — older drugs with harsh side effects — in favor of gene-targeting therapies, hormone blockers and immune system treatments. When chemo is used now, it’s sometimes for shorter periods or lower doses than it once was. For example, another study at...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized healthytime onetime Women's Health Source Type: news

Related Links:

This study investigated whether a single RT-led educational intervention was associated with a decrease in patient anxiety and increased knowledge about radiotherapy.
Source: Journal of Medical Imaging and Radiation Sciences - Category: Radiology Authors: Source Type: research
Authors: Niranjan A, Lunsford LD, Ahluwalia MS Abstract The most common primary cancers that metastasize to the brain are lung cancer, breast cancer, and melanoma. The established management approaches for brain metastasis include stereotactic radiosurgery, fractionated radiation therapy, and surgical resection. In the past the role of medical therapies in brain metastases was limited. In the last decade, our understanding of molecular drivers of brain metastases and CNS penetration of drugs across the blood-brain barrier has improved. The molecular targeted tyrosine kinase inhibitors have shown effectiveness in br...
Source: Progress in Neurological Surgery - Category: Neurosurgery Tags: Prog Neurol Surg Source Type: research
Conclusion: An extract of an artemisinin-deficient Artemisia annua herbal preparation exhibits potent anticancer activity against triple negative human breast cancer. New active ingredients of Artemisia annua extract with potential anticancer activity have been identified.Graphical Abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
The Healthcare Qualify Improvement Partnership (HQIP) has made recommendations to commissioners for improvements to services for COPD, breast cancer, lung cancer and other disease areas.
Source: NHS Networks - Category: UK Health Source Type: news
Publication date: Available online 16 May 2019Source: Journal of the American College of RadiologyAuthor(s): Diego López, Efrén J. Flores, Randy C. Miles, Gary Wang, McKinley Glover, Jo-Anne Shepard, Constance D. Lehman, Anand K. NarayanAbstractPurposeMillions of women undergo mammography screening each year, presenting an opportunity for radiologists to identify women eligible for lung cancer screening with low-dose chest CT (LCS) and smoking cessation counseling. The purpose of our study was to estimate the proportion of women eligible for LCS and tobacco cessation counseling among women reporting mammograp...
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
Publication date: Available online 14 May 2019Source: Journal of BiotechnologyAuthor(s): Savli Hakan, Sertdemir Nilufer, Aydin Duygu, Dursun Bilge, Kurtas Omer, Reka Seda, Sunnetci-Akkoyunlu Deniz, Eren-Keskin Seda, Uygun Kazim, Ozden Ercan, Isik Ulas, Cabuk Devrim, Demir Gulhan, Guzdolu Eda, Gokbayrak Merve, Aksu Maksut Gorkem, CAnturk Nuh Zafer, Cine NaciABSTRACTUse of plasma cell-free DNA genomic testing, also know as liquid biopsy, reveals information for early detection and monitoring of solid tumors. Our study reports the analysis of 113 lung and 18 breast cancer patients using commercially available platforms. Lung ...
Source: Journal of Biotechnology - Category: Biotechnology Source Type: research
In conclusion, miR-4319 dampened YAP expression to mitigate the tumorigenesis of NSCLC through inhibiting LIN28-mediated RFX5 stability, which offered an insight into the molecular mechanism underlying miR-4319 in NSCLC development.Graphical abstract
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
In conclusion, these findings suggest that FXT could be a promising lead compound to be used as a novel STAT3 inhibitor and potential antitumor agent for the treatment of NSCLC. PMID: 31080186 [PubMed - in process]
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research
In conclusion, miR-4319 dampened YAP expression to mitigate the tumorigenesis of NSCLC through inhibiting LIN28-mediated RFX5 stability, which offered an insight into the molecular mechanism underlying miR-4319 in NSCLC development. PMID: 31096145 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
This study aimed to describe direct cost and cost elements of all cancer types by different beneficial characteristics.MethodsThe research was a retrospective observational study based on inpatient and outpatient records with a primary diagnosis of cancer from 31 hospitals in 2016. Total cost and cost per time were analyzed by cancer type, sources (prescription medicines, consumables fee for diagnosis and surgery, and other health services), and beneficial characteristics (gender and age).ResultsA total of 30  224 eligible inpatient admissions and 485 391 outpatient visits were identified during the study period....
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Conferences | Genetics | Health | Herceptin | Hormonal Therapy | Hormones | Immunotherapy | Insurance | Insurers | Lung Cancer | Medicare | Merck | Research | Study | USA Health | Women